EVP and Head of Chemistry · Prelude Therapeutics Inc (PRLD)

Andrew Combs

A named executive officer of Prelude Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,631,289

Salary $406,461Stock awards $0

FY2020: $2,016,063

4th of 4 named executive officers at Prelude Therapeutics by FY2021 total.

4 named officers on file for Prelude Therapeutics, FY2021

Andrew Combs’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Prelude Therapeutics’s whole pay program stands against its peers

  • Prelude Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PRLD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Andrew Combs’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Andrew Combs compensation by year

Prelude Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Prelude Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$321,538$406,461
Bonus$0$0
Stock awards$0$0
Option awards$1,533,537$2,068,828
Non-equity incentive$160,988$156,000
Pension and deferred compensation$0$0
All other$0$0
Total$2,016,063$2,631,289

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Prelude Therapeutics Inc DEF 14A filed April 29, 2022, accession 0001564590-22-016626, and prior-year filings.

How this page was built: the Prelude Therapeutics Inc filed document, accession 0001564590-22-016626. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

$2.0M
$2.6M
FY20
FY21
SalaryNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU81,054$1,009,122—
Option48,634—$1.89
Option80,244—$12.85
Option95,000—$31.23

Per the Outstanding Equity Awards at Fiscal Year-End table in Prelude Therapeutics Inc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2021 proxy (filed April 29, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-04Grant or award derivative—230,000$0.00230,000
2025-03-25Purchase—100,000$0.69480,123
2025-02-04Grant or award derivative—175,000$0.00175,000
2024-12-23Purchase—60,000$1.37377,623
2024-12-20Purchase—3,075$1.15317,623
2024-03-01Grant or award derivative—150,000$0.00150,000

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Prelude Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Krishna VaddiChief Executive Officer$7,034,114
Brian PiperFormer Chief Financial Officer$2,908,023
Peggy ScherleChief Scientific Officer$2,633,099
Andrew Combs · this pageEVP and Head of Chemistry$2,631,289

The full Prelude Therapeutics compensation record

free company brief

This page is one person within Prelude Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Prelude Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Andrew Combs's compensation dossier · One-time report. No refunds.